GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cryofocus Medtech (Shanghai) Co Ltd (HKSE:06922) » Definitions » Debt-to-EBITDA

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Debt-to-EBITDA : -0.12 (As of Jun. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Cryofocus Medtech (Shanghai) Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cryofocus Medtech (Shanghai) Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$3.02 Mil. Cryofocus Medtech (Shanghai) Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$7.95 Mil. Cryofocus Medtech (Shanghai) Co's annualized EBITDA for the quarter that ended in Jun. 2023 was HK$-93.43 Mil. Cryofocus Medtech (Shanghai) Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -0.12.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Cryofocus Medtech (Shanghai) Co's Debt-to-EBITDA or its related term are showing as below:

HKSE:06922' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.11   Med: -0.07   Max: 0
Current: -0.11

HKSE:06922's Debt-to-EBITDA is ranked worse than
100% of 438 companies
in the Medical Devices & Instruments industry
Industry Median: 1.255 vs HKSE:06922: -0.11

Cryofocus Medtech (Shanghai) Co Debt-to-EBITDA Historical Data

The historical data trend for Cryofocus Medtech (Shanghai) Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryofocus Medtech (Shanghai) Co Debt-to-EBITDA Chart

Cryofocus Medtech (Shanghai) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
- -0.07 -0.10 -0.11

Cryofocus Medtech (Shanghai) Co Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial N/A - -0.08 -0.12 -0.10

Competitive Comparison of Cryofocus Medtech (Shanghai) Co's Debt-to-EBITDA

For the Medical Devices subindustry, Cryofocus Medtech (Shanghai) Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryofocus Medtech (Shanghai) Co's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cryofocus Medtech (Shanghai) Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cryofocus Medtech (Shanghai) Co's Debt-to-EBITDA falls into.



Cryofocus Medtech (Shanghai) Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cryofocus Medtech (Shanghai) Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.833 + 8.866) / -122.945
=-0.10

Cryofocus Medtech (Shanghai) Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.022 + 7.952) / -93.432
=-0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2023) EBITDA data.


Cryofocus Medtech (Shanghai) Co  (HKSE:06922) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Cryofocus Medtech (Shanghai) Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cryofocus Medtech (Shanghai) Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryofocus Medtech (Shanghai) Co (HKSE:06922) Business Description

Traded in Other Exchanges
N/A
Address
Building 15, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, CHN, 200120
Cryofocus Medtech (Shanghai) Co Ltd is a medical device company engaged in the research and development, manufacture and sale of cryoablation minimally-invasive interventional treatment technology and related medical products. It has two Core Products, the Bladder Cryoablation System and the Endoscopic Clip for Anastomosis. The Bladder Cryoablation System is a cryotherapy device designed for the treatment of bladder cancer. The Endoscopic Clip for Anastomosis is an anastomotic device for the closure of soft tissue in the digestive tract, which is one of the over-the-scope clips. Geographically company's key revenue is generated from China.
Executives
Wu Jianhui 2101 Beneficial owner
Li Hui 2202 Interest of your spouse
Lv Shiwen 2103 Interests held jointly with another person
Sun Xiaolu 2201 Interest of corporation controlled by you
Zhang Qian
Hang Zhou Bi Lin Xing Chuang Xin Tou Zi He Huo Qi Ye You Xian He Huo
Shang Hai Shi Di Sheng Wu Ke Ji You Xian Gong Si
Shang Hai Bi Lin Xing Zi Chan Guan Li You Xian Gong Si
Hang Zhou Bi Lin Xing Chuang Xin Tou Zi Guan Li He Huo Qi Ye You Xian He Huo
Ning Bo Lin Feng Sheng Wu Ke Ji You Xian Gong Si
Shang Hai Shi Di Shi Ye Fa Zhan You Xian Gong Si
Sheng Shan Zi Chan Guan Li Shang Hai You Xian Gong Si
Gan Shi Xiong
Su Zhou Gong Ye Yuan Qu Zhi Nuo Shang Wu Xin Xi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Gong Ye Yuan Qu Xin Jian Yuan Er Qi Chuang Ye Tou Zi Qi Ye You Xian He Huo 2101 Beneficial owner

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Headlines

No Headlines